Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LIPIDIL vs BEKYREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LIPIDIL (fenofibrate) is a fibric acid derivative that activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), leading to increased lipolysis and clearance of triglyceride-rich particles, and increased synthesis of apolipoproteins A-I and A-II.
BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.
Primary hypercholesterolemia or mixed dyslipidemia (as adjunct to diet),Severe hypertriglyceridemia,Prevention of pancreatitis in patients with hypertriglyceridemia
Treatment of chronic kidney disease in patients with type 2 diabetes,Reduction of albuminuria in chronic kidney disease
130 mg orally once daily.
1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.
Terminal elimination half-life of fenofibric acid is approximately 20 hours (range 15-25 hours). This supports once-daily dosing; steady-state is achieved after ~5 days.
Terminal elimination half-life: 12 hours (range 10-14 h); prolonged in renal impairment (up to 30 h in Cr Cl <30 m L/min)
Fenofibrate is metabolized primarily by glucuronidation; fenofibric acid is further metabolized via reduction to benzhydrol metabolite. Minor involvement of CYP450 enzymes, predominantly CYP3A4.
Primarily metabolized by CYP3A4; minor contributions from CYP2C8 and CYP2C9.
Primarily renal excretion of glucuronide conjugates; approximately 70% of a single oral dose is recovered in urine (mostly as fenofibric acid glucuronide), and about 6% is excreted in feces.
Renal: 70% (unchanged drug), Biliary/fecal: 30% (metabolites and unchanged drug)
Fenofibric acid is highly bound to plasma proteins, primarily albumin, with >99% binding.
95% bound to albumin and alpha-1-acid glycoprotein
Apparent volume of distribution (Vd/F) is approximately 0.9 L/kg, indicating distribution into total body water.
0.8-1.2 L/kg (indicates extensive tissue distribution)
Absolute bioavailability of fenofibrate (prodrug) is not determined; fenofibrate is rapidly converted to fenofibric acid with a relative bioavailability of approximately 81-96% compared to the micronized formulation when taken with food. Absorption is enhanced when taken with meals.
Oral: 60% (range 50-70%; first-pass metabolism reduces bioavailability)
GFR 30-89 m L/min: 130 mg once daily; GFR <30 m L/min: contraindicated.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not recommended for severe renal impairment (e GFR <30 m L/min/1.73 m²) due to lack of data.
Child-Pugh class A: 130 mg once daily; Child-Pugh class B or C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 0.5 mg/kg intravenously every 4 weeks; Child-Pugh C: not recommended.
Not recommended for use in pediatric patients.
Safety and efficacy not established in pediatric patients under 18 years.
No dose adjustment required, but monitor renal function due to age-related decline.
No specific dose adjustment required; consider age-related renal function and comorbidities.
There is no FDA black box warning for LIPIDIL.
None.
Hepatotoxicity: elevated liver enzymes reported; monitor liver function,Myopathy/rhabdomyolysis: increased risk when combined with statins or in renal impairment,Renal impairment: dose adjustment required; avoid in severe renal impairment,Cholelithiasis: increased bile cholesterol saturation may lead to gallstones, Pancreatitis: despite triglyceride reduction, pancreatitis can occur
Hyperkalemia: Monitor serum potassium regularly; avoid use with strong CYP3A4 inhibitors or potassium supplements.,Acute kidney injury: May occur; assess renal function before initiation.,Adrenal insufficiency: Not studied in patients with adrenal disorders.,Pregnancy: Limited data; avoid use unless benefit outweighs risk.
Severe renal impairment (e GFR < 30 m L/min),Active liver disease including primary biliary cirrhosis,Pre-existing gallbladder disease,Hypersensitivity to fenofibrate or any component,Nursing mothers (due to potential for tumorigenicity in animal studies)
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin),Serum potassium >5.0 m Eq/L at initiation,e GFR <15 m L/min/1.73 m² (not studied),Hypersensitivity to balcinrenone or any excipient
Take with food to enhance absorption. Avoid high-fat meals that may exacerbate hypertriglyceridemia. Grapefruit juice has minimal interaction but caution is advised with statin combinations. Alcohol should be limited or avoided due to potential for elevated triglycerides and hepatotoxicity.
No known food interactions. Avoid grapefruit juice if patient is on concurrent CYP3A4 substrates (though bevacizumab is not metabolized by CYP enzymes). Maintain adequate hydration to reduce risk of constipation, a common side effect.
Lipidil (fenofibrate) is contraindicated in pregnancy. Animal studies show fetal toxicity at high doses. Human data are insufficient, but risk cannot be excluded. First trimester: possible embryotoxicity; second and third trimesters: potential for fetal harm due to interference with lipid metabolism.
First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for fetal growth restriction and oligohydramnios.
Contraindicated during breastfeeding. Fenofibrate is excreted in breast milk in animal studies; M/P ratio unknown in humans. Potential for serious adverse effects in breastfed infants, including interference with fatty acid metabolism.
No human data on excretion in breast milk. M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects in nursing infant.
Lipidil is contraindicated in pregnancy; no dose adjustment recommended. Therapy should be discontinued upon conception or if pregnancy is planned. There are no established dose adjustments for pregnant women due to lack of safety data.
No specific dose adjustments recommended based on pharmacokinetic changes. However, monitor therapeutic effect and adjust dose as needed based on clinical response and tolerability.
Lipidil (fenofibrate) is a PPARα agonist used primarily for severe hypertriglyceridemia and mixed dyslipidemia. Monitor renal function at baseline and periodically; reduce dose in CKD (e GFR <60 m L/min). Avoid in severe hepatic impairment or gallbladder disease. Combines with statins but increases risk of myopathy; monitor for muscle symptoms. May raise serum creatinine and homocysteine levels. Tablet should be swallowed whole; do not crush or chew.
BEKYREE (bevacizumab-awwb) is a biosimilar to bevacizumab. Monitor for hypertension, proteinuria, and bleeding. Discontinue 28 days prior to elective surgery. Avoid use in patients with recent hemoptysis or serious hemorrhage. Infusion reactions may occur; premedicate with antihistamines and acetaminophen as per protocol.
Take with food to improve absorption and reduce stomach upset.,Avoid alcohol as it can worsen triglyceride levels and liver effects.,Report unexplained muscle pain, tenderness, or weakness immediately.,Inform your doctor if you have kidney or liver disease, or gallbladder problems.,This medication may increase the effects of blood thinners (warfarin); monitor INR closely.,Do not take if you are pregnant or breastfeeding without consulting your doctor.
Tell your doctor if you have a history of bleeding problems, blood clots, or recent surgery.,Avoid taking aspirin or NSAIDs unless prescribed by your doctor, as they increase bleeding risk.,Report any unusual bleeding, coughing up blood, or black/tarry stools immediately.,Women of childbearing age must use effective contraception during therapy and for 6 months after last dose.,Do not breastfeed during treatment and for 6 months after the last dose.,Monitor for signs of hypertension (severe headache, blurred vision) and proteinuria (foamy urine).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LIPIDIL vs BEKYREE, answered by our medical review team.
LIPIDIL is a Fibrate Antilipemic that works by LIPIDIL (fenofibrate) is a fibric acid derivative that activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), leading to increased lipolysis and clearance of triglyceride-rich particles, and increased synthesis of apolipoproteins A-I and A-II.. BEKYREE is a Antilipemic Agent that works by BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LIPIDIL and BEKYREE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LIPIDIL is: 130 mg orally once daily.. The standard adult dose of BEKYREE is: 1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LIPIDIL and BEKYREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LIPIDIL is classified as Category C. Lipidil (fenofibrate) is contraindicated in pregnancy. Animal studies show fetal toxicity at high doses. Human data are insufficient, but risk cannot be excluded. First trimester: . BEKYREE is classified as Category C. First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.